D. Gary Gilliland

Department of Hematology and Oncology, Brigham and Women's Hospital and Harvard Medical School

Affiliated withBrigham and Women's Hospital and Harvard Medical School

Research Area

Biography

D. Gary Gilliland has not added Biography.
If you are D. Gary Gilliland and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 19	2008

Other Publications

Article	Year
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood\| PubMed ID: 11756186	2002
Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications. Current opinion in oncology\| PubMed ID: 11790974	2002
Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation\| PubMed ID: 11846355	2002
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 12032333	2002
The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood\| PubMed ID: 12036890	2002
Role of FLT3 in leukemia. Current opinion in hematology\| PubMed ID: 12042700	2002
PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 12060771	2002
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer cell\| PubMed ID: 12086890	2002
Core-binding factors in haematopoiesis and leukaemia. Nature reviews. Cancer\| PubMed ID: 12094236	2002
Focus on acute leukemias. Cancer cell\| PubMed ID: 12124171	2002
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer cell\| PubMed ID: 12124172	2002
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer cell\| PubMed ID: 12124173	2002
The roles of FLT3 in hematopoiesis and leukemia. Blood\| PubMed ID: 12176867	2002
Genetics of myeloid leukemias. Annual review of genomics and human genetics\| PubMed ID: 12194988	2002
The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood\| PubMed ID: 12406902	2003
Molecular genetics of human leukemias: new insights into therapy. Seminars in hematology\| PubMed ID: 12447846	2002
A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood\| PubMed ID: 12515727	2003
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. The New England journal of medicine\| PubMed ID: 12660384	2003
MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer cell\| PubMed ID: 12676584	2003
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and i... Blood\| PubMed ID: 12676775	2003
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRÎ±-induced myeloproliferative disease. Cancer cell\| PubMed ID: 12781364	2003
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood\| PubMed ID: 12842979	2003
FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors. Best practice & research. Clinical haematology\| PubMed ID: 12935959	2003
The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood\| PubMed ID: 14630792	2004
Proteolytic processing in development and leukemogenesis. Cell\| PubMed ID: 14636551	2003
The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Current opinion in hematology\| PubMed ID: 14676627	2004
The role of signal transducer and activator of transcription factors in leukemogenesis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 14722044	2004
NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood\| PubMed ID: 14962911	2004
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. The Journal of clinical investigation\| PubMed ID: 14966562	2004
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 14976243	2004
Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemia. Cell cycle (Georgetown, Tex.)\| PubMed ID: 15020845	2004
Positive and negative regulatory roles of the WW-like domain in TEL-PDGFbetaR transformation. Blood\| PubMed ID: 15054045	2004
The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood\| PubMed ID: 15070659	2004
Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome. Seminars in oncology\| PubMed ID: 15175999	2004
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood\| PubMed ID: 15178581	2004
Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. The Journal of clinical investigation\| PubMed ID: 15199413	2004
Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood\| PubMed ID: 15256420	2004
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nature medicine\| PubMed ID: 15273746	2004
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood\| PubMed ID: 15345597	2005
Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer research\| PubMed ID: 15374944	2004
Blasts from the past: new lessons in stem cell biology from chronic myelogenous leukemia. Cancer cell\| PubMed ID: 15380509	2004
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 15448205	2004
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K\| PubMed ID: 15496975	2005
The molecular basis of leukemia. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program\| PubMed ID: 15561678	2004
Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL. The Journal of biological chemistry\| PubMed ID: 15569670	2005
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer cell\| PubMed ID: 15607963	2004
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer cell\| PubMed ID: 15710326	2005
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer cell\| PubMed ID: 15710330	2005
EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head. PLoS medicine\| PubMed ID: 15736989	2005
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood\| PubMed ID: 15784726	2005
Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation. Blood\| PubMed ID: 15784730	2005
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood\| PubMed ID: 15790786	2005
Leukaemia stem cells and the evolution of cancer-stem-cell research. Nature reviews. Cancer\| PubMed ID: 15803157	2005
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer cell\| PubMed ID: 15837627	2005
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood\| PubMed ID: 15860661	2005
Drug therapy for acute myeloid leukemia. Blood\| PubMed ID: 15870183	2005
JAK2 in myeloproliferative disorders is not just another kinase. Cell cycle (Georgetown, Tex.)\| PubMed ID: 15970705	2005
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood\| PubMed ID: 15972446	2005
Cancer biology: summing up cancer stem cells. Nature\| PubMed ID: 15988505	2005
The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clinic proceedings. Mayo Clinic\| PubMed ID: 16007902	2005
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood\| PubMed ID: 16030188	2005
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood\| PubMed ID: 16081687	2005
Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes. British journal of haematology\| PubMed ID: 16115143	2005
Genetics of myeloid malignancies: pathogenetic and clinical implications. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 16155011	2005
JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. British journal of haematology\| PubMed ID: 16197451	2005
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 16365288	2005
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer\| PubMed ID: 16369984	2006
Your health in the 21st century. Do stem cells cause cancer? Newsweek\| PubMed ID: 16375133	2005
X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK... Blood\| PubMed ID: 16434490	2006
Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood\| PubMed ID: 16434499	2006
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. The Journal of experimental medicine\| PubMed ID: 16446383	2006
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood\| PubMed ID: 16478879	2006
Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood\| PubMed ID: 16493009	2006
Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia. Methods in molecular medicine\| PubMed ID: 16502585	2006
Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 16606850	2006
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood\| PubMed ID: 16627759	2006
Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease. Blood\| PubMed ID: 16675706	2006
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood\| PubMed ID: 16675707	2006
Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 16690743	2006
Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best practice & research. Clinical haematology\| PubMed ID: 16781488	2006
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood\| PubMed ID: 16804112	2006
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS medicine\| PubMed ID: 16834459	2006
Cell-autonomous and -nonautonomous contributions of STAT1 in murine models of tumorigenesis. Cancer cell\| PubMed ID: 16843258	2006
Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer cell\| PubMed ID: 16843266	2006
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature\| PubMed ID: 16862118	2006
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood\| PubMed ID: 16868251	2006
Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 17068127	2006
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. British journal of haematology\| PubMed ID: 17107350	2006
JAK-2 mutations and their relevance to myeloproliferative disease. Current opinion in hematology\| PubMed ID: 17133099	2007
Jak2: normal function and role in hematopoietic disorders. Current opinion in genetics & development\| PubMed ID: 17208428	2007
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell\| PubMed ID: 17254969	2007
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell\| PubMed ID: 17254970	2007
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. The New England journal of medicine\| PubMed ID: 17267906	2007
The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell\| PubMed ID: 17320163	2007
The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. The Journal of clinical investigation\| PubMed ID: 17347684	2007
Oncogenes in myeloproliferative disorders. Cell cycle (Georgetown, Tex.)\| PubMed ID: 17351342	2007
A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood\| PubMed ID: 17360941	2007
Ott1(Rbm15) has pleiotropic roles in hematopoietic development. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 17376872	2007
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an... Blood\| PubMed ID: 17488875	2007
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. American journal of human genetics\| PubMed ID: 17564968	2007
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature reviews. Cancer\| PubMed ID: 17721432	2007
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer cell\| PubMed ID: 17785202	2007
Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin. Blood\| PubMed ID: 17827387	2007
A role for JAK2 mutations in myeloproliferative diseases. Annual review of medicine\| PubMed ID: 17919086	2008
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer cell\| PubMed ID: 17936561	2007
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nature genetics\| PubMed ID: 17994017	2008
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood\| PubMed ID: 18006699	2008
SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. Genes, chromosomes & cancer\| PubMed ID: 18064648	2008
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer cell\| PubMed ID: 18068628	2007
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood\| PubMed ID: 18216297	2008
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood\| PubMed ID: 18252861	2008
Structural and numerical variation of FLT3/ITD in pediatric AML. Blood\| PubMed ID: 18305215	2008
FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell stem cell\| PubMed ID: 18371346	2007
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer cell\| PubMed ID: 18394554	2008
Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood\| PubMed ID: 18559972	2008
Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore. Molecular cell\| PubMed ID: 18614052	2008
K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood\| PubMed ID: 18663146	2008
Deregulation of signaling pathways in acute myeloid leukemia. Seminars in oncology\| PubMed ID: 18692684	2008
Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Experimental hematology\| PubMed ID: 18723266	2008
Myeloproliferative disorders. Blood\| PubMed ID: 18779404	2008
Notch signaling specifies megakaryocyte development from hematopoietic stem cells. Cell stem cell\| PubMed ID: 18786418	2008
Going with the flow: JAK-STAT signaling in JMML. Cancer cell\| PubMed ID: 18835028	2008
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature\| PubMed ID: 18923525	2008
Ott1 (Rbm15) is essential for placental vascular branching morphogenesis and embryonic development of the heart and spleen. Molecular and cellular biology\| PubMed ID: 18981216	2009
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood\| PubMed ID: 19075190	2009
Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood\| PubMed ID: 19139084	2009
Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies. Blood\| PubMed ID: 19202126	2009
A radical bailout strategy for cancer stem cells. Cell stem cell\| PubMed ID: 19265655	2009
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. The Journal of clinical investigation\| PubMed ID: 19287095	2009
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nature genetics\| PubMed ID: 19287384	2009
The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood\| PubMed ID: 19401558	2009
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood\| PubMed ID: 19420352	2009
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell\| PubMed ID: 19490892	2009
Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell stem cell\| PubMed ID: 19497284	2009
[The OTT-MAL fusion oncogene: another Notch in megakaryoblastic leukemia]. MÃ©decine sciences : M/S\| PubMed ID: 19765378	2009
A progenitor cell origin of myeloid malignancies. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 19805346	2009
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature\| PubMed ID: 19847166	2009
Direct inhibition of the NOTCH transcription factor complex. Nature\| PubMed ID: 19907488	2009
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Science signaling\| PubMed ID: 19920251	2009
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood\| PubMed ID: 20008787	2010
Leukemia stem cells. Seminars in cancer biology\| PubMed ID: 20026405	2010
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood\| PubMed ID: 20068225	2010
The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. Blood\| PubMed ID: 20197553	2010
The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective. Current hematologic malignancy reports\| PubMed ID: 20425335	2006
Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis. Haematologica\| PubMed ID: 20494928	2010
Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem cells (Dayton, Ohio)\| PubMed ID: 20506303	2010
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer cell\| PubMed ID: 20541703	2010
Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20601445	2010
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nature medicine\| PubMed ID: 20616797	2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelod... Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 20733134	2010
mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell stem cell\| PubMed ID: 21040901	2010
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 21220608	2011
Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer research\| PubMed ID: 21505102	2011
Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification. Blood\| PubMed ID: 21653327	2011
Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood\| PubMed ID: 21765021	2011
Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood\| PubMed ID: 21873545	2011
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell\| PubMed ID: 21884932	2011
KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice. Blood\| PubMed ID: 22160378	2012
A Functional Role For The Histone Demethylase Utx In Normal And Malignant Hematopoietic Cells. Experimental hematology\| PubMed ID: 22306297	2012